August 21, 2019
 · 
1 min read

Click chemistry targets antibody-drug conjugates for the clinic

Bioorthogonal chemistry, already a workhorse of drug discovery research, prepares for the leap into human testing.

Researchers at the Memorial Sloan Kettering Cancer Center in New York are preparing the first test in humans of a new type of diagnostic that combines a radioisotope and antibody via bioorthogonal ‘click’ chemistry. The trial is expected to be a proof of principle of the clinical potential of bioorthogonal chemistry—reactions that can be performed in living systems without interfering with the surrounding biology.

Read more via this link.

Curious about what we do? Get in touch!

Logo-2

About    Our Technology   Pipeline    Join us    News    Contact

Contact
T +31 85 800 8550
info@tagworkspharma.com

Address
Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED  Nijmegen
The Netherlands

Stay updated

© Tagworks Pharmaceuticals, 2024 | Terms of use | Design by Ape to Zebra